Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG353

—

6996918a-41a9-530b-bc41-edee8c998f50

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.526
  • MYC_TARGETS_V1+0.497
  • G2M_CHECKPOINT+0.475
  • DNA_REPAIR+0.400
  • MYC_TARGETS_V2+0.379
  • OXIDATIVE_PHOSPHORYLATION+0.345
  • MITOTIC_SPINDLE+0.229
  • PI3K_AKT_MTOR_SIGNALING+0.193
  • PEROXISOME+0.147
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.124

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.456
  • TNFA_SIGNALING_VIA_NFKB-0.346
  • PANCREAS_BETA_CELLS-0.322
  • APICAL_SURFACE-0.315
  • INFLAMMATORY_RESPONSE-0.310
  • IL2_STAT5_SIGNALING-0.287
  • UV_RESPONSE_DN-0.284
  • KRAS_SIGNALING_UP-0.277
  • CHOLESTEROL_HOMEOSTASIS-0.272
  • ESTROGEN_RESPONSE_EARLY-0.221

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR33532767
breast-umap@18
—E0.847
2MDT-AP-0447
medullo-epn-umap@date-based
MedMedulloblastoma0.846
3TCGA-NC-A5HG-01A-11R-A26W-07
lung-landscapes@6
—cohortSQ10.844
4TCGA-66-2757-01A-01R-0851-07
lung-landscapes@6
—cohortMD10.839
5BS_TZVFR600
medullo-epn-umap@date-based
MedMedulloblastoma0.835
6TCGA-22-5481-01A-31R-1949-07
lung-landscapes@6
—cohortMD10.828
7504282dd-4fef-4f70-a709-6a545d00a263
colon-landscapes@1
——0.820
8ERR2208894
melanoma-umap@29
——0.819
9SRR8518168
breast-umap@18
—E0.818
1020090275.TNBC
breast-umap@18
—E0.814

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.526Inavolisib— uncovered
MYC_TARGETS_V10.497Inavolisib— uncovered
G2M_CHECKPOINT0.475Inavolisib— uncovered
DNA_REPAIR0.400Idelalisib— uncovered
MYC_TARGETS_V20.379Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.345Remibrutinib— uncovered
MITOTIC_SPINDLE0.229Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.193Inavolisib— uncovered
PEROXISOME0.147Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.124Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.117Inavolisib— uncovered
SPERMATOGENESIS0.107Inavolisib— uncovered
ADIPOGENESIS0.104Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.096Inavolisib— uncovered
GLYCOLYSIS0.095Inavolisib— uncovered
UV_RESPONSE_UP0.090Idelalisib— uncovered
MTORC1_SIGNALING0.083Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.075Idelalisib— uncovered
KRAS_SIGNALING_DN0.057Remibrutinib— uncovered
P53_PATHWAY0.046Idelalisib— uncovered